Liquid Biopsy for Detection of Driver Mutation in NSCLC

Liquid Biopsy for Detection of Driver Mutation in Diagnostic and Prognostic of NSCLC

The purpose of this study is to evaluate the diagnostic and prognostic efficacy of liquid biopsy in different specimens and in different methods compared with tissue detection .

Collect plasma and other specimens from patients who are newly diagnosed with NSCLC or with drug-resistant and plan to receive gene detection to complete the diagnostic test for liquid biopsy .Participants who come from diagnostic test and plan to receive tyrosine kinase inhibitors (TKI) therapy will be collected plasma and other specimens every month during the regiments and monitor the changes of driver motion to predict the prognosis of targeted therapy.

cohort 1

Inclusion Criteria:

• patients newly diagnosed with NSCLC confirmed by tissue biopsy and going to receive the detection of gene mutation or patients have obtained drug-resistance after receiving molecular target therapy and plan to re-biopsy.
• Age ≥ 18 years
• newly diagnosed patients have not received TKI and chemotherapy
• patients who are drug-resistant have not received next-generation TKI

Exclusion Criteria:

• patients who have more than one type of carcinoma
• patients who reject to sign the informed consent from

cohort 2

Inclusion Criteria:

• patients from cohort1 with sensitive driver mutation and plan to receive TKI therapy
• patients will have regular follow-up in Chinese people liberation army general hospital every month.

Exclusion Criteria:

• patients who are refused to provide the informed consent from